Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

What key factors are powering the surge in the alzheimer’s drugs market right now?

The market size for Alzheimer’s medications has significantly expanded in the last few years. The market, which was valued at $9.33 billion in 2024, is projected to reach $10.19 billion in 2025, representing a compound annual growth rate (CAGR) of 9.1%. Factors contributing to this growth during the historical period include an increase in the number of Alzheimer’s cases, investment in research and development, enhanced knowledge of disease mechanisms, worldwide health initiatives, and the promotion of public awareness and education.

How fast Is the alzheimer’s drugs market expected to grow, and what’s its future value?

In the forthcoming years, it’s predicted that the alzheimer’s drugs market will undergo robust expansion. The market is expected to escalate to $14.47 billion in 2029, exhibiting a compound annual growth rate (CAGR) of 9.2%. This projected growth within the forecast period is due to factors such as precision medicine strategies, focus on disease alteration, biomarker identification and authentication, patient-focused drug creation, and emphasis on non-pharmaceutical interventions. Key trends within the forecast period include varied therapeutic approaches, the application of digital health solutions, regenerative medicine, breakthroughs in diagnostic technologies, the incorporation of artificial intelligence (AI) in drug discovery and numerous partnerships and collaborations.

Get your alzheimer’s drugs market report here!

https://www.thebusinessresearchcompany.com/report/alzheimers-drugs-global-market-report

What are the leading drivers of growth in the alzheimer’s drugs market?

The increased incidence of Alzheimer’s disease is projected to boost the Alzheimer’s drug market’s expansion in the future. Alzheimer’s is a neurological disorder that progressively worsens, leading to shrinkage of the brain and cell death. Medications for Alzheimer’s are utilized to address memory loss, thinking and reasoning issues, and daily living challenges. These drugs can improve quality of life and help maintain autonomy. For example, a report by the Alzheimer’s Association – a US-based nonprofit organization focusing on Alzheimer’s care, support, and research, showed that the number of Americans aged 65 and up diagnosed with Alzheimer’s rose from 6.5 million in 2022 to an estimated 6.9 million in May 2024 . Hence, the growing incidence of Alzheimer’s disease is fuelling the expansion of the Alzheimer’s drug market.

What are the key segments defining the alzheimer’s drugs market?

The alzheimer’s drugs market covered in this report is segmented –

1) By Drugs: Donepezil, Rivastigmine, Galantamine, Memantine

2) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

3) By Application: Early To Moderate Stages, Moderate To Severe Stages

Subsegments:

1) By Donepezil: Oral Tablets, Oral Solution

2) By Rivastigmine: Oral Capsules, Oral Solution, Transdermal Patches

3) By Galantamine: Oral Tablets, Oral Solution, Extended-Release Capsules

4) By Memantine: Oral Tablets, Oral Solution, Extended-Release Capsules

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9040&type=smp

Who are the key players steering the development of the alzheimer’s drugs market?

Major companies operating in the alzheimer’s drugs market include AbbVie Inc., Daiichi Sankyo Company Limited, F Hoffmann-La Roche AG, Merck & Co Inc., Novartis AG, Biogen Inc., AstraZeneca PLC, Eisai Co Ltd., Eli Lilly and Company, H Lundbeck A/S, Pfizer Inc., Allergan PLC., Johnson & Johnson, Lupin Pharmaceuticals Inc., Actiza Pharmaceutical Private Limited, Neurotrope Inc., AC Immune SA, Adamas Pharmaceuticals Inc, Alzheon Inc., Anavex Life Sciences Corp, Axsome Therapeutics Inc., Cassava Sciences Inc., Cognition Therapeutics Inc., Cortexyme Inc., Denali Therapeutics Inc, EIP Pharma Inc., Enlivex Therapeutics Ltd., FORUM Pharmaceuticals Inc., Genentech Inc., Green Valley Pharmaceuticals LLC, Intra-Cellular Therapies Inc., Karuna Therapeutics Inc., Neurim Pharmaceuticals Ltd

What emerging trends are influencing the growth of the alzheimer’s drugs market?

Leading organizations in the Alzheimer’s medication market are pioneering innovative solutions such as treatments targeting amyloid plaque to enhance methods of treatment and improve results for patients. Therapies that target amyloid plaque focus on minimizing or halting the buildup of amyloid-beta plaques in the brain, a common approach for Alzheimer’s disease treatment. For example, in June 2024, the US-based Eli Lilly and Company received approval for Kisunla (donanemab-azbt) from the Food and Drug Administration (FDA), the US federal agency responsible for public health protection. Kisunla (donanemab-azbt) is the first of its kind, an amyloid plaque-targeting medication for early symptomatic Alzheimer’s disease. It works by assisting the body in eliminating excess amyloid plaques from the brain, these plaques are known to be linked with cognitive decline in Alzheimer’s patients. Kisunla is administered via an intravenous infusion every month. The initial treatment plan includes 700 mg for the first three doses, followed by 1400 mg for subsequent doses. Kisunla is specifically recommended for adults suffering from mild cognitive impairment (MCI) and mild dementia stages of Alzheimer’s disease, given they have confirmed amyloid pathology.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=9040

Which regions are most influential in expanding the alzheimer’s drugs market?

North Americawas the largest region in the Alzheimer’s drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the Alzheimer’s drugs market during the forecast period. The regions covered in the Alzheimer’s drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Browse Through More Similar Reports By The Business Research Company:

Cardiovascular Drugs Global Market Report 2022

https://www.thebusinessresearchcompany.com/report/cardiovascular-drugs-global-market-report

Alzheimer’s Disease Treatment Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/alzheimer-disease-treatment-global-market-report

Pharmaceutical Drugs And Biologics Logistics Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/pharmaceutical-drugs-and-biologics-logistics-market

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: